HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques

Vaccine

Volumn 31, Issue 36, 2013, Pages 3747-3755

  Li, Jinyao ^a   Valentin, Antonio ^a   Kulkarni, Viraj ^a   Rosati, Margherita ^a   Beach, Rachel Kelly ^a   Alicea, Candido ^a   Hannaman, Drew ^b   Reed, Steven G ^c   Felber, Barbara K ^a   Pavlakis, George N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Ichor Medical Systems Inc   (United States)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant; Antibody; Cellular responses; Dendritic cell maturation; Electroporation; Humoral responses; Immunization; Neutralizing antibody; Vaccination

Indexed keywords

ADJUVANT; DNA; DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 6; PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS DNA VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ELECTROPORATION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANT; ANTIBODY; CELLULAR RESPONSES; DENDRITIC CELL MATURATION; ELECTROPORATION; HUMORAL RESPONSES; IMMUNIZATION; NEUTRALIZING ANTIBODY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CROSS PROTECTION; DENDRITIC CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERLEUKIN-6; MACACA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 84880927219     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.037     Document Type: Article

References (50)

1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
2. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
3. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
4. Lai L., Kwa S., Kozlowski P.A., Montefiori D.C., Ferrari G., Johnson W.E., et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011, 204:164-173.
5. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
6. Flatz L., Cheng C., Wang L., Foulds K.E., Ko S.Y., Kong W.P., et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol 2012, 86:7760-7770.
7. Letvin N.L., Rao S.S., Montefiori D.C., Seaman M.S., Sun Y., Lim S.Y., et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011, 3:81ra36.
8. Patel V., Jalah R., Kulkarni V., Valentin A., Rosati M., Alicea C., et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci USA 2013, 110:2975-2980.
9. Lai L., Kwa S.F., Kozlowski P.A., Montefiori D.C., Nolen T.L., Hudgens M.G., et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012, 30:1737-1745.
10. Patel V., Valentin A., Kulkarni V., Rosati M., Bergamaschi C., Jalah R., et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 2010, 28:4827-4836.
11. Rosati M., Bergamaschi C., Valentin A., Kulkarni V., Jalah R., Alicea C., et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci USA 2009, 106:15831-15836.
12. Rosati M., von Gegerfelt A., Roth P., Alicea C., Valentin A., Robert-Guroff M., et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 2005, 79:8480-8492.
13. Kulkarni V., Jalah R., Ganneru B., Bergamaschi C., Alicea C., von Gegerfelt A., et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 2011, 29:6742-6754.
14. Yin J., Dai A., Lecureux J., Arango T., Kutzler M.A., Yan J., et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 2011, 29:6763-6770.
15. Cox K.S., Clair J.H., Prokop M.T., Sykes K.J., Dubey S.A., Shiver J.W., et al. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol 2008, 82:8161-8171.
16. Muthumani K., Bagarazzi M., Conway D., Hwang D.S., Manson K., Ciccarelli R., et al. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. Vaccine 2003, 21:629-637.
17. Hutnick N.A., Myles D.J., Bian C.B., Muthumani K., Weiner D.B. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 2011, 1:233-240.
18. Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320:760-764.
19. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22:358-366.
20. Pal R., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Hocker L., et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006, 348:341-353.
21. Pal R., Wang S., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Polyvalent DNA, et al. prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005, 34:226-236.
22. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26:3947-3957.
23. Kennedy J.S., Co M., Green S., Longtine K., Longtine J., O'Neill M.A., et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008, 26:4420-4424.
24. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
25. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992, 66:7176-7182.
26. Schwartz S., Felber B.K., Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992, 66:150-159.
27. Anderson R.C., Fox C.B., Dutill T.S., Shaverdian N., Evers T.L., Poshusta G.R., et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 2010, 75:123-132.
28. Arias M.A., Van Roey G.A., Tregoning J.S., Moutaftsi M., Coler R.N., Windish H.P., et al. Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. Plos One 2012, 7:e41144.
29. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone (R) adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
30. Olugbile S., Kulangara C., Bang G., Bertholet S., Suzarte E., Villard V., et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated plasmodium falciparum protein PFF0165c. Infect Immun 2009, 77:5701-5709.
31. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts bcg and protects against multidrug-resistant mycobacterium tuberculosis. Sci Transl Med 2010, 2:53ra74.
32. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G.C., Vedvick T.S., et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27:3063-3071.
33. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K., et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988, 167:332-344.
34. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196.
35. Jin H., Kang Y., Zheng G., Xie Q., Xiao C., Zhang X., et al. Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines. Virology 2005, 337:183-191.
36. Li J.Y., Jin H.L., Zhang A.L., Li Y.J., Wang B., Zhang F.C. Enhanced contraceptive response by co-immunization of DNA and protein vaccines encoding the mouse zona pellucida 3 with minimal oophoritis in mouse ovary. J Gene Med 2007, 9:1095-1103.
37. Zhang A.L., Li J.Y., Zhao G., Geng S., Zhuang S.Z., Wang B., et al. Intranasal co-administration with the mouse zona pellucida 3 expressing construct and its coding protein induces contraception in mice. Vaccine 2011, 29:6785-6792.
38. Geng S., Yu Y., Kang Y., Pavlakis G., Jin H., Li J., et al. Efficient induction of CD25- iTreg by co-immunization requires strongly antigenic epitopes for T cells. BMC Immunol 2011, 12:27.
39. Jin H., Kang Y., Zhao L., Xiao C., Hu Y., She R., et al. Induction of adaptive T regulatory cells that suppress the allergic response by coimmunization of DNA and protein vaccines. J Immunol 2008, 180:5360-5372.
40. Li J., Geng S., Xie X., Liu H., Zheng G., Sun X., et al. Caveolin-1-mediated negative signaling plays a critical role in the induction of regulatory dendritic cells by DNA and protein coimmunization. J Immunol 2012, 189:2852-2859.
41. Jin H., Xiao C., Geng S., Hu Y., She R., Yu Y., et al. Protein/DNA vaccine-induced antigen-specific Treg confer protection against asthma. Eur J Immunol 2008, 38:2451-2463.
42. Li J., Jin H., Zhang F., Du X., Zhao G., Yu Y., et al. Treatment of autoimmune ovarian disease by co-administration with mouse zona pellucida protein 3 and DNA vaccine through induction of adaptive regulatory T cells. J Gene Med 2008, 10:810-820.
43. Jin J., Ding Z., Meng F., Liu Q., Ng T., Hu Y., et al. An immunotherapeutic treatment against flea allergy dermatitis in cats by co-immunization of DNA and protein vaccines. Vaccine 2010, 28:1997-2004.
44. Zhang W., Jin H., Hu Y., Yu Y., Li X., Ding Z., et al. Protective response against type 1 diabetes in nonobese diabetic mice after coimmunization with insulin and DNA encoding proinsulin. Hum Gene Ther 2010, 21:171-178.
45. Kuwahara M., Konishi E. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clin Vaccine Immunol 2010, 17:1560-1566.
46. Ishikawa T., Takasaki T., Kurane I., Nukuzuma S., Kondo T., Konishi E. Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes Infect 2007, 9:1089-1095.
47. Imoto J.I., Konishi E. Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. Viral Immunol 2005, 18:205-212.
48. Masalova O.V., Lesnova E.I., Pichugin A.V., Melnikova T.M., Grabovetsky V.V., Petrakova N.V., et al. The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization. Vaccine 2010, 28:1987-1996.
49. Imoto J., Konishi E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 2007, 25:1076-1084.
50. Jaworski J.P., Krebs S.J., Trovato M., Kovarik D.N., Brower Z., Sutton W.F., et al. Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. Plos One 2012, 7:e31464.